Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics

Nagoya Journal of Medical Science

Volumn 74, Issue 1-2, 2012, Pages 39-49

  Saito, Hiroshi ^a,e   Tomita, Akihiro ^b   Ohashi, Haruhiko ^c   Maeda, Hideaki ^a   Hayashi, Hisao ^d   Naoe, Tomoki ^b  

^a Kawamura Hospital   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d AICHI GAKUIN UNIVERSITY   (Japan)

^e not available   (Japan)

Author keywords

Chronic hepatitis C; Determination of ferritin and hemosiderin; Iron overload; Serum ferritin kinetics; Storage iron metabolism

Indexed keywords

BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; DEFERASIROX; FERRITIN; HEMOSIDERIN; IRON; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ANEMIA; ARTICLE; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; DRUG EFFECT; FEMALE; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; IRON OVERLOAD; JAPAN; KINETICS; LIVER; MALE; METABOLISM; MIDDLE AGED;

ANEMIA; BENZOIC ACIDS; BIOLOGICAL MARKERS; COMPUTER SIMULATION; FEMALE; FERRITINS; HEMOCHROMATOSIS; HEMOSIDERIN; HEPATITIS C, CHRONIC; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; JAPAN; KINETICS; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TRIAZOLES;

EID: 84860615336     PISSN: 00277622     EISSN: 21863326     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ambross G, Zweier JL, Jacobs WE, Weisfeld ML, Fluharty JL. Improvement of postischemic myocardial function and metabolism by administration of desferrioxamine at the time of reflow. The role of iron in the pathogenesis of reperfusion injury. Circulation, 1987; 76 (4): 906-915.
2. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J, 1989; 117 (5): 1177-1188.
3. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. New Engl J Med, 1988; 319 (16): 1047-1052.
4. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood, 1997; 89 (3): 739-761.
5. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa A, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once a daily oral iron chelator, in patients with b-thalassemia. Blood; 2006; 107 (9): 3455-3462.
6. Miyazawa K, Ohyashiki K, Urabe A, Hatta T, Nakao S, Ozawa K, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Taniguchi J, Tanii H Rojkjaer L, Omine M. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and ironoverload: a Phase I study in Japan. Int J Hematol, 2008; 88 (1): 73-81.
7. Shoden A, Gabrio BW, Finch CA. The relationship between ferritin and hemosiderin in rabbits and man. J Biol Chem, 1953; 204 (2): 823-830.
8. Addison GM, Beamish MR, Hales CN, Hodgkins M, Jacobs A, Llewellin P. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. J Clin Path, 1972; 25 (4): 326-329.
9. Jacobs A, Worwood M. Ferritin in serum: clinical and biochemical implications. New Engl J Med, 1975; 292 (18): 951-956.
10. Saito H. Studies on storage iron; dynamic behavior of ferritin and hemosiderin under various experimental conditions. Nagoya J Med Sci, 1958; 21 (4): 288-300.
11. Milder MS, Cook JD, Finch CA. Idiopathic hemochromatosis: an interim report. Medicine, 1980; 59 (1): 34-49.
12. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver disease. Gastroenterology, 1975; 68 (3): 525-533.
13. van Oost BA, van den Beld B, van Asbeck BS, Marx JJM. Monitoring of intensive phlebotomy therapy in iron overload by serum ferritin assay. Am J Hematol, 1985; 18 (1): 7-12.
14. Saito H. Serum ferritin. In the Clinical Disorders of Iron Metabolism-From Iron Deficiency to Iron Overload-, edited by H. Saito. pp. 92-94, 1999, Iyaku (Medicine & Drug) Journal Co., Ltd. (in Japanese), Osaka and Tokyo.
15. Hayashi H, Takikawa T, Nishimura N, Yano T, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess iron. Am J Gastroenterology, 1994; 89 (7): 986-988.
16. Shiono Y, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Yano M, Yoshioka K, Saito H. Body iron stores and iron restoration rate in Japanese patients with chronic hepatitis C as measured during therapeutic iron removal revealed neither increased body iron stores nor effects of C282Y and H63D mutations on iron indices. Nagoya J Med Sci, 2001; 64 (1-2): 51-57.
17. Haskins D, Stevens AR Jr, Finch SC, Finch CA. Iron metabolism; iron stores in man as measured by phlebotomy. J Clin Invest, 1952; 31(6): 543-547.
18. Fleming RE, Bacon BR. Perspective. Orchestration of iron homeostasis. N Engl J Med, 2005; 352 (17): 1741-1744.
19. Saito H, Sargent T, Parker HG, Lawrence JH. Iron absorption in normal man. Proc. 9th Congress International Society of Haematology, September 6-15, 1962, Mexico City, 1962; 3: 511-522.
20. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Brit J Haemat, 1994; 87 (1): 171-184.
21. Angelucci E, Giovagnoni A, Valeri G, Paci E, Ripalti M, Muretto P, McLaren C, Brittenham GM, Lucarelli G. Limitation of magnetic resonance imaging in measurement of hepatic iron. Blood, 1997; 90 (12): 4736-4742.
22. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects, J Clin Path, 1973; 26 (10):770-772.
23. Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. Blood, 1986; 68 (3): 726-731.
24. Saito H. Clinical aspects on total iron-binding capacity (TIBC), unsaturated iron-binding capacity (UIBC) and serum iron (SI) Acta Haematol Jpn, 1978; 41 (6): 1277-1284.
25. Saito H and Hotta T. Iron-binding proteins for the diagnosis and therapy of iron deficiency states. Acta Haematol Jpn, 1986; 49 (8): 196-204.
26. Saito H, Kawamura Y. Storage iron decrease rates and their clinical significance in iron deficiency patients following intravenous iron therapy. Jpn J Clin Hematol (in Japanese), 1999; 40 (11): 112-118.
27. Saito H, Maeda H. Method for determining the amount of blood loss using the storage iron decrease rate as obtained from serum ferritin after intravenous iron therapy. Jpn J Clin Hematol (in Japanese), 2004; 45 (11): 1177-1180.
28. Finch S, Haskins D, Finch CA. Iron metabolism; hematopoiesis following phlebotomy; iron as a limiting factor. J Clin Invest, 1950; 29 (8): 1078-1086.
29. Finch CA, Hegsted M, Kinney TD, Thomas ED, Rath CE, Haskins D, Finch S, Fluharty RG. Iron metabolism; the pathophysiology of iron storage. Blood, 1950; 5 (11): 983-1008.
30. Jacobs A. Editorial Review: low molecular weight intracellular iron transport compounds. Blood, 1977; 50 (3): 433-439.
31. Konijn AM, Glickstein H, Vaisman B, Myron-Holze EG, Itzchak N, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood, 1999; 94 (6): 2128-2134.
32. Matioli GT, Baker RF. Denaturation of ferritin and its relationship with hemosiderin. J Ultrastruct Research, 1963; 8 (5-6): 477-490.
33. Miyazaki E, Kato J, Kobune M, Okumura K, Nishitani N, Arosio P, Niitsu Y. Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload. Gut, 2002; 50 (3): 413-419.